| Product NDC: | 61958-0101 |
| Proprietary Name: | Vistide |
| Non Proprietary Name: | CIDOFOVIR |
| Active Ingredient(s): | 75 mg/mL & nbsp; CIDOFOVIR |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 61958-0101 |
| Labeler Name: | Gilead Sciences, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020638 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19960626 |
| Package NDC: | 61958-0101-1 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (61958-0101-1) > 5 mL in 1 VIAL, SINGLE-USE |
| NDC Code | 61958-0101-1 |
| Proprietary Name | Vistide |
| Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (61958-0101-1) > 5 mL in 1 VIAL, SINGLE-USE |
| Product NDC | 61958-0101 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | CIDOFOVIR |
| Dosage Form Name | INJECTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 19960626 |
| Marketing Category Name | NDA |
| Labeler Name | Gilead Sciences, Inc. |
| Substance Name | CIDOFOVIR |
| Strength Number | 75 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],DNA Polymerase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient] |